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Background: Access to Hepatitis C (HCV) care is low among HIV-infected individuals, highlighting the need for new
models to deliver care for this population.
Methods: Retrospective cohort analysis that compared the number of HIV patients who initiated HCV therapy:
hepatology (2005–2008) vs. HIV primary care model (2008–2011). Logistic-regression modeling was used to
ascertain factors associated with HCV therapy initiation and achievement of sustained viral response (SVR).
Results: Of 196 and 163 patients that were enrolled in the HIV primary care and hepatology models, 48 and 26
were treated for HCV, respectively (p = 0.043). The HIV/HCV-patient referral rate did not differ during the two study
periods (0.10 vs. 0.12/patient-yr, p = 0.18). In unadjusted analysis, predictors (p < 0.05) of HCV treatment initiation
included referral to the HIV primary care model (OR: 1.7), a CD4+ count ≥400/mm3 (OR: 1.8) and alanine
aminotranferase level ≥63U/L (OR: 1.9). Prior psychiatric medication use correlated negatively with HCV treatment
initiation (OR: 0.6, p = 0.045). In adjusted analysis the strongest predictor of HCV treatment initiation was CD4+
count (≥400/mm3, OR: 2.1, p = 0.01). There was no significant difference in either clinic model (primary care vs.
hepatology) in the rates of treatment discontinuation due to adverse events (29% vs. 16%), loss to follow-up (8 vs.
8%), or HCV SVR (44 vs. 35%).
Conclusions: Using a HIV primary care model increased the number of HIV patients who initiate HCV therapy with
comparable outcomes to a hepatology model.
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Access to hepatitis C (HCV) treatment remains low in
HIV-infected individuals in the USA [1-3], resulting in
increased morbidity and cost due to HCV related com-
plications [4,5].
The following factors account in part for the low treat-
ment rates of HCV in the HIV population: increased
prevalence of competing medical co-morbidities [6], on-
going substance/alcohol dependence and neuropsychi-
atric disease [7]. Additional disincentives for patients to* Correspondence: ecachay@ucsd.edu
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reproduction in any medium, provided the orseek HCV treatment include: low efficacy and severe
side effects associated with conventional HCV therapies
(pegylated interferon and ribavirin) [8]; long waiting
time prior to HCV intake appointment in sub-specialty
clinics [9]; and commuting to a different location from
where they routinely receive their HIV care [10,11].
In April 2008, the University of California at San Diego
(UCSD) transitioned from a hepatology specialty model to
an HIV primary care hepatitis program for the manage-
ment of HCV in HIV-infected patients without advanced
cirrhosis. Many centers around the country with a high
burden of HIV/HCV co-infection have implemented simi-
lar multidisciplinary co-infection programs, but there is
little data describing the structure, processes, and out-
comes of these programs. Thus, we sought to compareLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between a prior hepatology-managed co-infection clinic
and a subsequent HIV primary care managed co-infection
clinic after the first three years of transition.
Methods
Study design and patients
We compared two adult cohorts: (1) UCSD hepatology
specialty model (1 Jan 2005–31 March 2008) and (2) the
UCSD Owen hepatitis co-infection clinic (1 April 2008–30
July 2011). Inclusion criteria required: (1) a documented
clinical decision regarding HCV treatment eligibility; (2) if
treated, HCV treatment consisting of pegylated interferon
and ribavirin. The study was approved by the UCSD
Human Research Protection Program.
Description of HIV primary care model
The UCSD Owen clinic cares for more than 3,000 HIV-
infected patients of whom approximately 20% are co-
infected with HCV. Prior to April 2008 a team of
hepatologists managed a once weekly clinic for assessment
of HIV/HCV patients. There were no explicit inclusion
criteria for referral to the traditional hepatology-based
clinic. Historically, HIV providers made referral decisions
based on their own referral criteria. The new hepatitis co-
infection primary care model also operates as one clinic
session per week and is staffed by three HIV clinicians
with Infectious Diseases certification, a psychiatrist, two
clinical pharmacists specialized in HIV care, one health
educator and a substance counselor. There was no change
in procedures for patient referral to the primary care man-
aged co-infection clinic nor were there any other struc-
tural changes to the HIV clinic during the transition
process; all HIV patients under care with viral hepatitis
co-infection could be referred by their HIV primary care
provider for evaluation. Every patient underwent a de-
tailed clinical, laboratory and imaging (ultrasound and/or
abdomino-pelvic computer tomography) assessment for
staging degree of liver disease according to standard of
care and ruling out indirect evidence of advanced liver dis-
ease and/or portal hypertension [12]. Patients with HCV
genotype 1 or 4 were offered a liver biopsy performed by
the interventional radiology service unless patients de-
clined the procedure. Esophagogastroduodenoscopies
when required were completed by the gastroenterology
service. Our minimal requirements for HCV treatment
eligibility were: (1) undetectable HIV viral load and CD4
cell count ≥ 200/cm3 if on antiretroviral therapy; (2) CD4
cell count ≥ 500/cm3 irrespective of HIV viral load value if
naïve to antiretroviral therapy; (3) absence of Child B or C
liver cirrhosis; (4) stable concurrent medical co-morbidity;
(5) favorable recommendation from the team’s psych-
iatrist; (6) registration in the San Diego needle exchange
program in the case of ongoing parenteral drug use withdocumentation of controlled HIV infection as in (1) and
(2), plus documentation of no missed clinic appointments
during HCV staging process; and (7) alcohol sobriety for
at least 3 months prior to HCV treatment initiation.
Homeless patients were required to receive all weekly
pegylated interferon injections in clinic.
HCV treatment monitoring strategies and role of
pharmacists in the HIV primary care model
Following favorable consideration to initiate HCV therapy,
a patient was assigned to one of three groups for HCV
treatment monitoring: Group 1 had patients without
major significant medical co-morbidity, social barriers and
no on-going illicit substance use. Group 2 comprised pa-
tients with on-going substance use and/or homelessness,
Group 3 included patients with severe neuropsychiatric
disease (i.e. prior suicidal attempts) and/or medical
co-morbidities (i.e. history of congestive heart failure).
Patients were followed by physicians and pharmacist spe-
cialized in HIV where frequency of follow-up and labora-
tory testing was based on monitoring group assignment
(Additional file 1: Table S1 and Additional file 2: Table
S2). Pharmacists verified: (1) potential medication interac-
tions; (2) HIV antiretroviral adherence; (3) HCV health
education; (4) insurance coverage for access to HCV
medication; and (5) patient understanding of HCV medi-
cation dosing, administration, and possible side effects.
During HCV treatment, HIV pharmacists assist in moni-
toring: (1) adherence to HCV therapy; (2) critical labora-
tory results; (3) HCV medication and adjunctive therapy
access during treatment course; and (4) unexpected medi-
cation interactions/clinical complaints not reported by the
patient to physicians.
Study outcomes
The primary outcome was the difference in the number
of referred patients who initiated HCV therapy in both
cohorts during the study period. Secondary outcomes
were: (1) referral rates by HIV primary care providers
for HCV treatment consideration and (2) proportion of
patients that following HCV therapy achieved sustained
viral response (SVR).
Independent variables
The following independent variables were assessed: (1)
sociodemographic (age, sex, race/ethnicity, HIV risk fac-
tor); (2) HIV related (CD4 cell count, HIV viral load and
proportion of patients on antiretroviral therapy); (3) HCV
viral load and genotype; (4) histological severity of liver
disease according to modified Knodell score; (5) neuro-
psychiatric history, including proportion of patients on
any psychotropic medications; (6) history of self-reported
illicit substance and/or alcohol use within the last 3
months of HCV treatment evaluation by completion of
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the substance abuse counselor and (7) laboratory values
[hemoglobin, platelet count, alanine aminotransferase
(ALT), international normalized ratio (INR)].
Statistics
Baseline comparison of clinical characteristics between
patients referred to the two clinic models was evaluated
using exact Wilcoxon tests for continuous and Fisher’s
test for categorical variables. Among patients referred to
each clinic model differences in reasons for deferring
HCV therapy were explored using chi-square analyses.
Bivariate analyses were used to explore the effect of each
independent variable in predicting the decision for HCV
treatment initiation. Then, we fitted a multiple logistic
regression model to adjust for confounding and effect
modification of variables associated with HCV therapy
initiation using the co-variates found to be significant in
prior bivariate analysis (p <0.10). We estimated referral
rates as the number of referrals per patient-year of
follow-up during the study period. The beginning of
follow-up for the hepatology or primary care group was
defined as the later of either the date of first date of each
cohort study period or the date of first visit to each co-
infection clinic model. The end of follow-up for each
group was the earlier of either the date of last visit to
the co-infection clinic model or the end of the two re-
spective study periods. The referral rate ratio and 95%
confidence interval was estimated with its associated p-Figure 1 Flow of included patients.value. Analyses were performed using NCCSS version
8.0 (Kaysville, Utah, USA).
Results
From a total of 667 and 616 HIV/HCV co-infected pa-
tients during the studied periods, 256 and 203 were re-
ferred for HCV treatment evaluation to the HIV primary
care and hepatology models, respectively. The HCV
prevalence was similar during studied periods, HIV pri-
mary care model (17%) and hepatology (18%). The patient
referral rate for HCV treatment did not differ during the 2
study periods, 0.12 vs. 0.10/patient-year for HIV primary
care and hepatology models [difference −0.02, 95% confi-
dence intervals (CI) −0.03 to 0.06; p = 0.18]. Main reasons
for exclusion of 100 patients after initial visit are shown in
Figure 1. The final study cohorts were composed of 196
and 163 patients for the HIV primary care and the
hepatology models, respectively. Of note there was no dif-
ference in the proportion of patients excluded in both
clinic models due to prior HCV treatment null-response
(11/196 vs. 6/163; p = 0.39), Figure 1.
Patients referred to the HIV primary care model were
older (median 48 vs. 45 years), had a higher proportion
of non-hispanics (85 vs. 74%) and reported more fre-
quently heterosexual sex as HIV risk factor (24 vs. 15%)
than those referred to the hepatology model. They also
had higher median CD4+ cell counts (431 vs. 372/mm3)
and platelet counts (208 vs. 184 × 103/mm3) at the time
of HCV treatment consideration (Table 1). There were
Table 1 Characteristics of the patients assessed for hepatitis C treatment consideration according to clinic model
Clinic model Hepatology HIV primary care P
value(n = 163) (n = 196)
Median age − years (range) 45(26–73) 48(19–75) 0.02a
Sex: Male (%) 137(84) 165(84) 0.97b
Race









Gay/bisexual 79 78 0.003c
Heterosexual 24 46




Median CD4+ cell count − cells/mm3 (range)1 372 (29–1179) 431 (38–1612) 0.05a
Median HIV load − log10 copies/mL (range) 2.6 (2.6–5.8) 2.6 (2.6–6.6) 0.12
a
Number on HAART therapy −% 132 (81) 172 (88) 0.08b
Hepatitis C genotype2
Genotype 1,4 125 158 0.68c
Genotype 2,3 31 35
Median HCV load − log10 copies/mL (range)
3 6.29 (1.9–8.4) 6.43 (2.2–8.4) 0.43a
Liver biopsy scores 4
F0-2 39 42 0.95c
F3,4 37 39
Any neuropsychiatry history – % 100 (61%) 119 (61%) 0.85b
On any psychiatry medications −% 75 (46%) 88 (45%) 0.83b
Drugs or alcohol use within 3months of HCV treatment consideration
No 71 115 0.0001c
yes 45 72
unknown 47 9
Median hemoglobin levels − g/dL (range) 14.7 (9–18.7) 14.3 (7.7–17.6) 0.13a
Median platelet count −1000/mm3 (range) 184 (44–531) 208 (41–548) 0.004a
Median ALT − U/L (range) 68 (20–980) 57 (12–1280) 0.51a
Median INR (range) 1.1 (0.9–2.3) 1.0 (0.9–2.6) 0.05a
ALT = Alanine aminotransferase ; AST = Aspartate aminotransferase; INR = International normalized ratio.
1 CD4+ counts available in 150 of 163 patients in the hepatology model and in all patients in HIV primary care model.
2 HCV genotype was not available in seven patients in hepatology model and one in HIV primary care model.
3 Liver biopsies: 70 in hepatology and 67 in HIV primary care models.
4 Two patients in the hepatology model had no available HCV viral load.
a Wilcoxon Rank-Sum Test.
b Chi-square Test.
c Fisher’s exact Test.
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Table 2 Characteristics of the patients treated for hepatitis C according to clinic model and treatment outcomes
Clinic model Hepatology HIV primary care P
value(n = 26) (n = 48)
Median age − years (range) 44 (27–62) 49 (19–61) 0.18a
Sex: Male (%) 23 (88) 38 (79) 0.32b
Race








Gay/bisexual 8 21 0.008c
Heterosexual 5 14




Median CD4+ cell count − cells/mm3 (range) 375 (149–1179) 522 (130–1142) 0.02a
Number with undetectable HIV load (%) 22 (85) 29 (83) 0.88b
Hepatitis C genotype2
Genotype 1/4 19 39 0.42b
Genotype 2/3 7 9
Median HCV load − log10 copies/mL (range) 6.04 (5.1–7.7) 6.41 (3.0–7.6) 0.88
a
Liver biopsy scores 1
F0-2 8 12 0.37c
F3,4 9 23
Number with relapse after prior HCV treatment (%) 5 (19) 5 (11) 0.29b
Any neuropsychiatry history – % 17 (65) 23 (48) 0.15b
On any psychiatry medications −% 11 (42) 15 (31) 0.34b
Drugs or alcohol use within 3months of HCV treatment consideration
No 12 32 0.0001c
Yes 5 16
Unknown 9 0
Median hemoglobin levels − g/dL (range) 14.8 (11.1–16.9) 14.5(12.1–16.6) 0.17a
Median platelet count −1000/mm3 (range) 178 (56–367) 224 (113–418) 0.01a
Median ALT − U/L (range) 71 (22–980) 64 (19–1087) 0.48a
Median INR (range) 1.1 (0.9–1.4) 1.0 (0.9–1.2) 0.69a
HCV treatment outcomes
№ Patients with rapid viral response (%) 4 (15) 12 (25) 0.34b
№ Patients with complete early viral response (%) 9 (35) 26 (54) 0.11b
№ Patients with end of treatment response (%) 12 (46) 24 (50) 0.75b
№ Patients with sustained viral response (%) 9 (35) 21 (44) 0.45b
№ Patients who discontinued HCV therapy due to non-viral response (%) 8 (31) 9 (19) 0.24b
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Table 2 Characteristics of the patients treated for hepatitis C according to clinic model and treatment outcomes
(Continued)
№ Patients who discontinued HCV therapy due to treatment-related side effects (%) 4 (15) 14 (29) 0.16b
№ Patients lost to follow-up (%) 2 (8) 4 (8) 0.92b
1 Liver biopsies were not performed in 2 and 6 patients with genotype 1 in the hepatology and HIV primary care models respectively.
a Wilcoxon Rank-Sum Test.
b Chi-square Test.
c Fisher’s exact Test.
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patients in plasma HIV or HCV viral load, HCV geno-
type distribution, liver fibrosis score, proportion of pa-
tients -receiving HIV therapy, -with neuropsychiatric
history, -on psychotropic medications. Among patients
referred to the HIV primary care model, 37% reported
use of drugs or heavy alcohol within 3 months of HCV
treatment consideration (Table 1).
While in the HIV primary care model a higher propor-
tion of patients (19 vs. 13%) chose to defer HCV therapy
due to personal reasons (e.g. did not want to request
time off at work), in the hepatology model more patients
failed to initiate HCV therapy due to loss-to-follow
up (29 vs. 14%), overall comparison χ2 15.6, df = 8, p =
0.03 (Figure 1).Treatment rates and predictors of Hepatitis C treatment
More patients were treated for HCV in the HIV primary
care model than in the hepatology model (48 vs. 26, p =
0.043). This difference was more apparent in the second
year of implementation of the HIV primary care model,
when comparing the proportion of patients treated for
HCV by year of study periods: year 1 (9 vs. 13%), year 2
(35 vs. 11%), year 3 (44 vs. 28%), for HIV primary care
vs. hepatology models, respectively, χ2 8.1, df = 2,
p =0.02.
Patients treated in the HIV primary care model had a
higher median CD4+ cell count (522 vs. 375/mm3), plate-
let count (224 vs. 178 × 103/mm3, p = 0.01) and frequency
of drugs or alcohol use within 3 months of HCV therapy
evaluation (33 vs. 19%). Among those treated for HCV,
there were no differences between clinic models in the
age, race/ethnicity, HIV/HCV viral load, proportion on
HIV therapy, HCV genotype distribution, liver fibrosis
score, relapse after prior HCV treatment or prevalence of
psychiatric disease (Table 2). When comparing clinical
characteristics of HCV treated and untreated patients
within each model, in the hepatology model there were no
clinical variables associated with the decision to initiate
HCV treatment. However, patients treated for HCV under
the HIV primary care model had higher CD4+ cell counts,
lower rates of psychiatric illness, and were prescribed
fewer psychotropic medications (Table 3). Using bivariate
categorical analysis, independent predictors of HCVtherapy initiation included being referred to the HIV pri-
mary care model [odds ratio (OR) 1.8, 95% CI 1.1–2.9,
p = 0.04]; having a higher CD4+ count (≥400/mm3, OR:
1.8, 95% CI 1.1–3.0) and ALT levels (> 63 U/L, OR: 1.9,
95% CI 1.2–2.9). Prior psychiatric medication use corre-
lated negatively with HCV treatment initiation (OR: 0.6,
95% CI 0.3–0.99). Logistic regression analysis adjusting
for all aforementioned significant variables showed that
the strongest predictor of HCV treatment initiation was
CD4+ count (≥400/mm3, OR: 2.1, 95% CI 1.2–3.6, p =
0.01) whereas a history of prior psychiatric medication use
decreased the chances of HCV treatment initiation (OR:
0.5, 95% CI 0.3–0.9, p = 0.02), (Table 4).Outcomes of HCV treatment
Similar proportions of patients achieved undetectable
HCV viral load -at week 4 (rapid viral response [RVR]), -
at week 12 (complete early viral response [cEVR]) and at
week 48 (end of treatment response [ETR]) in both models
(HIV primary care vs. hepatology): RVR [12/48(25%) vs. 4/
26(15%)], cEVR [26/48(54%) vs. 9/26(35%)] and ETR (24/
48(50%, vs. 12/26(46%)]. Twenty-one of 48 patients (44%)
in the HIV primary care and 9 of 26 patients (35%) in the
hepatology model achieved HCV SVR (p =0.45).
When comparing both models (primary care vs.
hepatology), there were no differences in the overall HCV
treatment discontinuations rates [27/48(56%) vs. 14/26
(54%), p = 0.84] or cause-specific reasons HCV-treatment
discontinuation rates: (1) non-viral response [9 /48 (18%)
vs. 8/26 (31%), p = 0.24]; (2) HCV therapy-related adverse
events [14/48 (29%) vs. 4/26 (16%), p =0.19]; and loss to
follow-up (4/ 48 (8%) vs. 2/26 (8%), p = 0.92]. The median
time for HCV treatment discontinuation due to adverse
events in the HIV primary care model was 12 weeks
(range 1–55) and was comparable to the hepatology
model (median 8 weeks, range 1–40). The reasons for
treatment discontinuation in the hepatology model (n = 4)
were hematologic (2) and neuropsychiatric (2) side effects.
In the HIV primary care model, main reasons for adverse-
events HCV treatment discontinuation (n = 14) were
neuropsychiatric (7) and somatic (7) side effects. The som-
atic side effects included: severe fatigue (3), anorexia /weight
loss (2), dizziness (1) and skin rash (1). In the HIV primary
care model, 16 (33%) HCV treated patients were actively
Table 3 Comparison of characteristics of the treated vs. untreated patients for hepatitis C according to clinic model
Clinic Model Hepatology HIV Primary care
Treated Not treated P Treated Not treated P
(n = 26) (n = 137) (n = 48) (n = 148)
Median age − years (range) 44 (27–62) 45 (26–73) 0.73a 49 (19–61) 48 ( 23–75) 0.46a
Sex: Male (%) 23 (89) 114 (83) 0.50b 38 (79) 127 (86) 0.27b
Race
White 21 94 0.46c 32 106 0.63c
Black 4 35 13 37
Other/unknown 1 8 2 5
Ethnicity
Hispanic 5 30 0.64c 7 19 0.59c
Not-Hispanic 19 102 41 16
Unknown 2 5 0 3
HIV risk factors
Gay/bisexual 8 71 0.18c 21 57 0.33c
Heterosexual 5 19 14 32
Intravenous drug use 1 2 0 8
Hemophilia 3 5 0 5
combination 3 22 11 36
Other/unknown 6 18 2 10
Median CD4+ cell count − cells/mm3 (range) 375 (149–1179) 371 (29–
1025)
0.68a 522 (130–1142) 388 (38–1612) 0.005a
Number of patients on HIV therapy (%) 22 (85%) 110 (80%) 0.61b 44 (92%) 128 (87%) 0.74b
Number with undetectable HIV load (%) 22 (85%) 95 (69%) 0.11b 40 (83%) 115 (78%) 0.41b
Hepatitis C genotype1
Genotype 1/4 19 106 0.32c 39 119 0.90b
Genotype 2/3 7 24 9 26
Median HCV load − log10 copies/mL (range)
2 6.0 (5.1–7.7) 6.3 (1.9–8.4) 0.71a 6.4 (3.01–7.6) 6.4 (2.2–8.4) 0.19a
Liver biopsy scores
F0-2 8 31 0.10c 12 30 0.19c
F3-4 9 28 13 26
unknown 9 78 23 92
Any neuropsychiatry history – % 17 (65%) 83(61%) 0.65b 23(48%) 96(65%) 0.04b
On any psychiatry medications −% 11 (42%) 64(47) 0.68b 15(31%) 73(49) 0.03b
Drugs or alcohol use within 3months of HCV treatment
consideration
No 12 59 0.55c 32 83 0.15c
Yes 5 40 16 56
Unknown 9 38 0 9
Median hemoglobin levels − g/dL (range) 14.8 (11.1–
16.9)





Median platelet count −1000/mm3 (range) 178 (56–367) 185 (44–531) 0.47a 224 (113–418) 207 (41–548) 0.18a
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Table 3 Comparison of characteristics of the treated vs. untreated patients for hepatitis C according to clinic model
(Continued)
Median ALT − U/L (range) 71 (22–980) 67 (20–488) 0.56a 64 (19–1087) 56 (12–1280) 0.25a
Median INR (range) 1.1 (0.9–1.4) 1.1 (0.9–2.3) 0.33a 1.0 (0.9–1.2) 1.0 (0.9–2.6) 0.66a
1 In the hepatology model (7) and HIV primary care model (3) patients had no available genotype, all in untreated group, there were no patients with genotype
#4 in treated groups.
2 Two patients in the untreated group in the hepatology model had no available HCV viral load.
a Wilcoxon Rank-Sum Test.
b Chi-square Test.
c Fisher’s exact Test.
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drugs and 4 were homeless. None of the treated homeless
patients were lost to follow-up.
Among patients treated in the HIV primary care
model, 17 were considered high-risk: substance use and/
or homelessness (n = 10) and severe psychiatric and/or
medical comorbidities (n = 7). The group of ‘high-risk’
patients was assigned to special HCV treatment monitor-
ing strategies as described in Additional file 1: Table S1.
There were no statistical differences between high-risk vs.
non high-risk patients in the rates of SVR, discontinua-
tions due to non-viral response or HCV therapy-related
adverse events or loss to follow-up (Table 5). However, the
difference in point estimates for loss to follow-up (18% vs.
3% [p = 0.08] for high and non-high risk, respectively)
partially validates the criteria we used to identify high
risk patients.
Discussion
Our comparison of the performance of an HIV primary
care model for the treatment of HCV among HIV-infected
patients in comparison to a subspecialty hepatology model
allows the following conclusions to be made: (1) In the
HIV primary care model there were more patients treated
for HCV and fewer were lost to follow-up; (2) HCV treat-
ment referral rates did not differ during two study periods;
(3) discontinuation rates were similar in both models des-
pite the increased prevalence of ongoing substance use in
the HIV primary care model; (4) the rate of HCV cure
(SVR) was similar in both clinic models.
The idea of using an HIV primary care model for the
treatment of HCV is not new [8,14-17]. However, a
novel component of our approach was the integration of
HIV clinical pharmacists to enhance protocol adherence
and patient safety. Undoubtedly, the role of the pharma-
cists is becoming more prominent since the introduction
of HCV direct acting antivirals in co-infected individ-
uals, where attention to medication interactions is par-
ticularly important [18].
The patient referral rate for HCV treatment did not in-
crease during the HIV primary care model, but referred
patients had less obvious clinical or laboratory signs of de-
compensated liver disease such as thrombocytopenia or
coagulopathy (Table 2). It is not clear whether this was theresult of the increased awareness among HIV providers
about importance of HCV treatment in the HIV primary
care model. What is known is that in the HIV primary
care model, 33% of patients treated for HCV had history
of ongoing substance use and 4 patients were homeless.
Despite this ‘high risk population’ treated for HCV by the
HIV primary care model, the proportions of HCV treat-
ment discontinuation (either due to adverse events or loss
to follow-up) and cure were similar to the hepatology
model. Moreover, the treatment outcomes in the high-risk
patients were similar to the non-high risk patients treated
in the HIV primary care model. In particular there was no
difference in the rate of treatment discontinuation due to
adverse events (Table 5). We acknowledge that our sam-
ples size was small to detect as significant differences be-
tween high-risk and non-high risk treated patients. But
the message to highlight is that the collaborative monitor-
ing strategy use by the HIV primary care model allowed
the HCV cure of patients that may have been rendered
unfavorable HCV treatment candidates in other sub-
specialty models [2]. The finding that patients with un-
stable psychiatric conditions, higher HIV viral loads and
lower CD4 cell counts were less likely to be treated in the
HIV primary care model was in line with the Owen Clinic
protocol of working prospectively with patients to link
them to care and, once they are more stable and engaged,
initiate HCV therapy [19]. This contrasted with the lack of
association with any of the studied variables to predict
HCV therapy initiation in the hepatology model.
The present study found no significant differences in
the rates of HCV SVR and discontinuation of HCV ther-
apy due to adverse events, however, the SVR trend was
greater in patients treated on the HIV primary care clinic
(44 vs. 35%) despite having almost double discontinuations
due to adverse events of patients treated by the hepatology
clinic (29 vs. 16%), perhaps due our lack of sample size to
detect those differences as significant (e.g. current sample
size has 10% power to detect a difference of 9% in SVR as
significant). In the absence of a difference in the propor-
tion of patients with viral relapse after prior HCV therapy
in both treatment models, we believe that this observation
may be explained by unmeasured clinical factors such as:
1) potential better interleukin-28B gene polymorphism al-
lele profile in patients treated in the HIV primary care
Table 4 Predictors of Hepatitis C treatment among patients referred to the hepatology (n = 163) and HIV primary care




valueOR (95% CI) OR (95% CI)
Hepatitis C treatment
(HIV primary care vs. hepatology model ) 1.7 (1.0–2.9) 0.04 1.6 (0.9–2.8) 0.08
CD4+ cell count 1
(≥400 vs. < 400 cells/mm3) 1.8 (1.1–3.03) 0.03 2.1 (1.2–3.6) 0.01
Having detectable HIV load
(≥400 vs. < 400 copies/mL) 0.5 (0.3–1.1) 0.09 0.6 (0.3–1.1) 0.09
On any psychiatry medications
(any vs. none) 0.6 (0.3–0.99) 0.04 0.5 (0.3–0.9) 0.02
Alanine aminotransferase levels
(≥63 vs. < 63U/L) 1.9 (1.2–2.9) 0.002 1.4 (0.8–2.3) 0.3
Any neuropsychiatry history
(yes vs. no) 0.7 (0.4–1.2) 0.17
Age − years
Per year increase 1.0 (0.9–1.03) 0.88
Sex − biological
(male vs. female) 1.2 (0.6–2.3) 0.65
Race
(white vs. non-white) 1.2 (0.6–2.5) 0.61
Ethnicity:
(non-hispanic vs. hispanic) 1.6 (0.2–13.4) 0.68
HIV risk factors
Men having sex with men Reference
Heterosexual 1.6 (0.9–3.2) 0.14
Intravenous drug use 0.4 (0.1–3.6) 0.44
Hemophilia 1.3 (0.3–5.1) 0.68
Combination 1.1 (0.5–2.1) 0.86
Hepatitis C genotype 2
(1/4 vs. 2/3) 0.8 (0.4–1.5) 0.50
Liver biopsy scores 3
(Proportion F3-4 vs. F0-2) 1.2 (0.6–2.5) 0.55
Drugs or alcohol use within 3 months of
HCV evaluation4
(yes vs. no) 0.7 (0.4–1.3) 0.24
HCV load − log10 copies/mL
5
(>6.33 vs. ≤ 6.33) 0.8 (0.5–1.4) 0.46
Hemoglobin levels
(>14.1 vs. ≤ 1 4.1 g/dL) 1.5 (0.8–2.6) 0.13
Platelet count
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Table 4 Predictors of Hepatitis C treatment among patients referred to the hepatology (n = 163) and HIV primary care
models (n = 196) in unadjusted and adjusted analyses (Continued)
(>139 vs. ≤ 139 − 1000/mm3) 1.3 (0.8–2.1) 0.31
INR levels
(>1.1 vs. ≤1.1) 0.5 (0.2–1.3) 0.16
1CD4+ counts available in 150 of 163 patients in the hepatology model and in all patients in HIV primary care model.
2 HCV genotype was not available in seven patients in hepatology model and one in HIV primary care model.
3 Liver biopsies: 70 in hepatology and 67 in HIV primary care models.
4 No data available in 47 patients in the hepatology model and in 9 patients in the HIV primary care model.
5 Two patients in the hepatology model had no available HCV viral load.
Table 5 Characteristics and outcomes of patients treated for hepatitis C in the HIV primary care model dichotomized
according to risk category based on assigned HCV treatment monitoring group*
Clinic model High-risk Non-high-risk P
value(n = 17) (n = 31)
Median age − years (range) 49 (19–61) 47 ( 33–61) 0.77a
Sex: Male (%) 14 (82) 24 (77) 0.68b
Race




Hispanic 2 5 0.68c
Not-Hispanic 15 26
Median T CD4+ cell count − cells/mm3 (range) 515(130–1136) 529(170–1140) 0.55a
Number with undetectable HIV load (%) 14 (82) 26 (84) 0.91b
Hepatitis C genotype
Genotype 1/4 13 26 0.53b
Genotype 2/3 4 5
Median HCV load − log10 copies/mL (range) 6.44(4.05–7.46) 6.40(3.0–7.6) 0.73
a
Liver biopsy scores 1
F0-2 4 8 0.51c
F3,4 6 7
Median Hemoglobin levels − g/dL (range) 14.5(12.9–15.8) 14.4(12.1–16.6) 0.63a
Median Platelet count −1000/mm3 (range) 191(113–418) 227(119–402) 0.38a
Median ALT − U/L (range) 85(22–301) 56(19–1087) 0.08a
HCV treatment outcomes
№ Patients with Sustained viral response (%) 5(29) 16(52) 0.14b
№ Patients who discontinued HCV therapy due to non-viral response (%) 2(12) 7(23) 0.36b
№ Patients who discontinued HCV therapy due to treatment-related side effects (%) 6(35) 8(26) 0.49b
№ Patients lost to follow-up (%) 3(18) 1(3) 0.08b
* High-risk patients comprised patients with substance use and/or homelessness (n = 10) and severe psychiatry and/or medical comorbidities (n = 7).
1 Liver biopsies were not performed in 6 patients with genotype 1 in the high-risk (n = 3) and non-high risk (n = 3) respectively.
a Wilcoxon Rank-Sum Test.
b Chi-square test.
c Fisher’s exact test.
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http://www.aidsrestherapy.com/content/10/1/9model [20], since this test was not available in our institu-
tion at the time we performed study; 2) a positive effect of
HIV primary care model in motivating patients while on
HCV therapy that led to improved adherence and hence
chances of cure in those who were able to tolerate HCV
therapy [21]. This study has important limitations. First,
this was not a randomized clinical trial; rather the aim was
to compare the performance of 2 clinic-based models with
balanced and overall comparable study populations. Sec-
ond, the HIV primary care model did not treat patients
with advanced cirrhosis given that these individuals are
more prone to develop severe adverse events. Thus, our
findings do not apply to patients with advanced liver dis-
ease, who still stand to benefit from specialized care by
hepatologists. Third, we cannot rule out that the increas-
ing rates of HCV treatment initiation over time in the
HIV primary care model could be the result of secular
trends: (a) aging of cohort and more urgency for treat-
ment, (albeit we found no difference in liver fibrosis scores
in both cohorts when liver biopsies were performed); (b)
concurrent emphasis in the literature of epidemiologic
evidence that liver disease is one of the leading causes of
death in HIV-infected people, which may have motivated
more treatment [22]. It could be argued that HCV treat-
ment uptake rate in the HIV primary care model was not
ideal (25%). However, our reported HCV-treatment rates
are higher than a recently reported aggressive program to
engage HIV/HCV co-infected patients in care sponsored
by the United States National Institutes of Health [23] and
similar to many European countries,[24] despite the fact
we had considerably less accrual time than other clinic-
based studies [16]. We believe that our study results
underestimate the positive impact of the HIV primary care
model in the HCV treatment uptake rate, since 23 pa-
tients in this model were excluded from the analysis be-
cause: (1) Three patients were still receiving HCV therapy
and therefore we could not assess their final outcomes; (2)
twenty patients who were staged and eligible for conven-
tional HCV therapy within study period elected to wait
for HCV protease inhibitors availability and initiated HCV
treatment right before or after 30 July 2011, (Figure 1).
The fact that 10% of patients in both cohorts
presented with advanced cirrhosis and were not eligible
for HCV therapy highlights the importance of reducing
disparities in access to HCV care in the HIV population
[3,25]. New HCV therapies offer higher chances of cure,
simpler and hopefully less toxic regimens [26,27]. How-
ever, to scale up HCV treatment among the HIV
infected population, we will need an inclusive collabora-
tive approach that reduces the negative referral bias of
physicians when making HCV treatment decisions in
vulnerable populations with ongoing barriers to care
[22,28,29]. We believe that the HIV primary care model
could be useful in other settings and countries burdenedby the high prevalence of HCV and difficult to treat
urban, poor, marginalized populations that require both
more efficacious HCV therapies and newer collaborative
models of care such as the one described here [30].
In conclusion, in this exploratory analysis, the use of
an HIV primary care model supported by pharmacists
specialized in HIV care increased the number of patients
who initiate and successfully finish HCV therapy with
comparable virological outcomes to a subspecialty
hepatology model, highlighting the importance of in-
creasing the absolute number of HIV-infected patients
treated for HCV at any given time.
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